New drug targets genetic weakness in deadly brain tumor
NCT ID NCT06105619
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial tests a new drug called vebreltinib (PLB1001) in people with a recurrent form of glioblastoma that has a specific genetic change (ZM fusion gene). The study compares vebreltinib to standard chemotherapy to see if it helps people live longer. About 84 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vebreltinib (PLB1001)
What this could lead to
If successful, this could provide a new targeted treatment option for people with a specific genetic subtype of recurrent glioblastoma, potentially improving survival.
What could go wrong
This is an early-to-mid-stage trial with only 84 participants. The drug may not prove more effective than standard chemotherapy, and side effects are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Tiantan Hospital,Capital Medical University
Beijing, Beijing Municipality, 100070, China